This is a completive renewal application for years 6-10 of Program Project Grant HL081588 entitled the Zimmerman Program for the Molecular and Clinical Biology of VWD. This project began as a means of characterizing patients diagnosed with VWD in the USA and correlating them at a molecular, laboratory phenotype, and clinical phenotype within our country as well as with cohorts studied in Canada and the European Union. This PPG has identified problems with the fidelity of the historical VWD diagnosis and problems with using certain tests that perform poorly with newly define common polymorphisms in African American. Project 1 (Montgomery) proposes studies to improve the fidelity of the diagnosis of VWD and studies approaches to better contrast the clinical, clinical lab, and research correlation of the VWD diagnosis. Some newer pilot studies will also study the impact of VWD on clinical menorrhagia and Quality of Life studies in VWD patients. Project 2 (Haberichter) studies the in vivo and in vitro correlates of VWF mutations. In the mouse, clearance mechanisms will be defined and whether an individual, with accelerated clearance as the reason for type 1C VWD, has increased clearance through normal pathways or increased clearance through pathologic pathways. Project 3 (Lillicrap/Goodeve explores broader mechanisms for reduced plasma, and/or cellular, VWF. Within this PPG and in both the Canadian and European Union Cohorts, subjects have been identified with quite low VWF but in whom no coding region mutation of VWF are identified. Individually, these studies have insufficient numbers to systematically study this phenomenon, but collectively this group is expected to be enabling. The Administrative Core not only oversees the day-to-day management of this Program but also maintains a supporting clinical network of Primary and Secondary Clinical Centers. The Clinical Laboratory Core performs the clinical laboratory testing (needed by all three projects), the coding sequence of VWF, and will coordinate the next-generation sequencing the full VWF gene (Project 1 and 3) and GWAS-associated sequencing. Taken together this PPG will set the stage for the appropriate diagnosis and phenotypic understanding of VWD - both in the US and throughout the world.

Public Health Relevance

This PPG is tightly focused on von Willebrand Disease that is a very common clinical bleeding disorder. In some studies its prevalence may be as high as 1-2% of the general population. Based on the NHLBI Guidelines (2006), the importance of under-diagnosis and over-diagnosis are major Public Health issues. This PPG and its three tightly interactive projects is focused on addressing these issues at a clinical, diagnostic and a molecular level. (End of Abstract)

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Link, Rebecca P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Medical College of Wisconsin
Schools of Medicine
United States
Zip Code
Goodeve, A C; Pavlova, A; Oldenburg, J (2014) Genomics of bleeding disorders. Haemophilia 20 Suppl 4:50-3
Fahs, Scot A; Hille, Matthew T; Shi, Qizhen et al. (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123:3706-13
de Brasi, C; El-Maarri, O; Perry, D J et al. (2014) Genetic testing in bleeding disorders. Haemophilia 20 Suppl 4:54-8
Laffan, Mike A; Lester, Will; O'Donnell, James S et al. (2014) The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 167:453-65
Hampshire, Daniel J; Goodeve, Anne C (2014) p.P2063S: a neutral VWF variant masquerading as a mutation. Ann Hematol 93:505-6
Elbatarny, M; Mollah, S; Grabell, J et al. (2014) Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia 20:831-5
Castaman, G; Hillarp, A; Goodeve, A (2014) Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis. Haemophilia 20 Suppl 4:65-70
Shida, Yasuaki; Rydz, Natalia; Stegner, David et al. (2014) Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and ?2?1-mediated collagen binding in thrombus formation. Blood 124:1799-807
Rusu, Luiza; Andreeva, Alexandra; Visintine, David J et al. (2014) G protein-dependent basal and evoked endothelial cell vWF secretion. Blood 123:442-50
Brott, David A; Katein, Anne; Thomas, Heath et al. (2014) Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 42:672-83

Showing the most recent 10 out of 49 publications